174 related articles for article (PubMed ID: 25897332)
1. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism.
Yang Y; Ran J; Sun L; Sun X; Luo Y; Yan B; Tala ; Liu M; Li D; Zhang L; Bao G; Zhou J
Theranostics; 2015; 5(7):656-66. PubMed ID: 25897332
[TBL] [Abstract][Full Text] [Related]
2. Induction of acetylation and bundling of cellular microtubules by 9-(4-vinylphenyl) noscapine elicits S-phase arrest in MDA-MB-231 cells.
Cheriyamundath S; Mahaddalkar T; Kantevari S; Lopus M
Biomed Pharmacother; 2017 Feb; 86():74-80. PubMed ID: 27939522
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.
Gao J; Huo L; Sun X; Liu M; Li D; Dong JT; Zhou J
J Biol Chem; 2008 Apr; 283(14):8802-9. PubMed ID: 18222923
[TBL] [Abstract][Full Text] [Related]
4. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation.
Zhou J; Gupta K; Aggarwal S; Aneja R; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2003 Apr; 63(4):799-807. PubMed ID: 12644580
[TBL] [Abstract][Full Text] [Related]
5. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.
Landen JW; Lang R; McMahon SJ; Rusan NM; Yvon AM; Adams AW; Sorcinelli MD; Campbell R; Bonaccorsi P; Ansel JC; Archer DR; Wadsworth P; Armstrong CA; Joshi HC
Cancer Res; 2002 Jul; 62(14):4109-14. PubMed ID: 12124349
[TBL] [Abstract][Full Text] [Related]
6. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.
Aneja R; Vangapandu SN; Lopus M; Viswesarappa VG; Dhiman N; Verma A; Chandra R; Panda D; Joshi HC
Biochem Pharmacol; 2006 Aug; 72(4):415-26. PubMed ID: 16780803
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Mishra RC; Gundala SR; Karna P; Lopus M; Gupta KK; Nagaraju M; Hamelberg D; Tandon V; Panda D; Reid MD; Aneja R
Bioorg Med Chem Lett; 2015; 25(10):2133-40. PubMed ID: 25891106
[TBL] [Abstract][Full Text] [Related]
9. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Landen JW; Hau V; Wang M; Davis T; Ciliax B; Wainer BH; Van Meir EG; Glass JD; Joshi HC; Archer DR
Clin Cancer Res; 2004 Aug; 10(15):5187-201. PubMed ID: 15297423
[TBL] [Abstract][Full Text] [Related]
10. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
11. Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma.
Altinoz MA; Topcu G; Hacimuftuoglu A; Ozpinar A; Ozpinar A; Hacker E; Elmaci İ
Neurochem Res; 2019 Aug; 44(8):1796-1806. PubMed ID: 31292803
[TBL] [Abstract][Full Text] [Related]
12. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
13. CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration.
Li D; Gao J; Yang Y; Sun L; Suo S; Luo Y; Shui W; Zhou J; Liu M
Cell Cycle; 2014; 13(6):974-83. PubMed ID: 24552808
[TBL] [Abstract][Full Text] [Related]
14. Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis.
Ye K; Zhou J; Landen JW; Bradbury EM; Joshi HC
J Biol Chem; 2001 Dec; 276(50):46697-700. PubMed ID: 11679575
[TBL] [Abstract][Full Text] [Related]
15. Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase.
Delgado M; Chambers TC
Cell Cycle; 2018; 17(14):1784-1796. PubMed ID: 29995568
[TBL] [Abstract][Full Text] [Related]
16. Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation.
Rong R; Jiang LY; Sheikh MS; Huang Y
Oncogene; 2007 Dec; 26(55):7700-8. PubMed ID: 17563743
[TBL] [Abstract][Full Text] [Related]
17. Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways.
Delgado M; Rainwater RR; Heflin B; Urbaniak A; Butler K; Davidson M; Protacio RM; Baldini G; Edwards A; Reed MR; Raney KD; Chambers TC
J Biol Chem; 2022 Jun; 298(6):101939. PubMed ID: 35436470
[TBL] [Abstract][Full Text] [Related]
18. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
19. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.
Ye K; Ke Y; Keshava N; Shanks J; Kapp JA; Tekmal RR; Petros J; Joshi HC
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1601-6. PubMed ID: 9465062
[TBL] [Abstract][Full Text] [Related]
20. The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells.
Lysaght J; Verma NK; Maginn EN; Ryan JM; Campiani G; Zisterer DM; Williams DC; Browne PV; Lawler MP; McElligott AM
Int J Oncol; 2013 Jan; 42(1):239-46. PubMed ID: 23135704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
